California's Hansen Medical inked a distribution deal with a Chinese medical device company for its intravascular robotic system, a feather in Hansen's cap as it looks to expand commercialization for its device.
Dr. Reddy's Laboratories is looking to expand its market footprint, eyeing as much as $1 billion in potential deals and higher-end products like generic injectable drugs to chart growth and diversify its offerings.
U.K. contractor Ergomed has made Asian landfall, opening an office in Taiwan with eyes on forging traditional CRO deals and signing risk-sharing agreements with drugmakers.
After issuing an import alert last year for an IPCA Laboratories API plant in India where employees had been falsifying drug testing results and deleting failed tests, the FDA began looking at its operations further upstream and has now banned products from two of IPCA's finished product facilities.
India has given consumers a way to complain about the availability or pricing of drugs. By providing an online portal and mobile app through which consumers can vent their grievances, Indian authorities are trying to turn the country's vast population into a disaggregated army of whistleblowers.
Merck KGaA is the latest company to join Big Pharma's recent round of executive musical chairs. The German drugmaker is promoting deputy chief executive Stefan Oschmann to replace current CEO Karl-Ludwig Kley as the company's top dog.
After rolling out its long-delayed Shan5 vaccine in November, Sanofi's Indian affiliate, Shantha Biotechnics, is ready to provide up to 37 million doses, having already started the process on Tuesday.
Not long after Gilead Sciences' high-priced hep C super drugs Sovaldi, and then combo drug Harvoni, hit the market, the California drugmaker struck deals with 11 generic drugmakers to make cut-rate versions available, and affordable, in 91 developing countries. But Gilead is not as generous as it might seem, Doctors Without Borders claims.
Vivo Capital has closed an oversubscribed eighth fund at $750 million to invest in later-stage pharma and medical device companies in the U.S. and revenue-stage companies in greater China. That's precisely twice the size of its prior fund, which closed at $375 million in January 2012.
A Malaysian drugmaker has bulked up its manufacturing capacity as it faces drugmakers from other countries building plants there to grab a piece of a market that is seeing the kind of growth hard to come by in other parts of the world.